West Pharmaceutical Services to Present at the CJS 25th Annual "New Ideas for the New Year" Investor Conference
Werte in diesem Artikel
EXTON, Pa., Jan. 6, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that Cindy Reiss-Clark, Sr. VP and Chief Commercial Officer; Chad Winters, VP of Finance and Chief Accounting Officer; and John Sweeney, VP of Investor Relations, will present at the CJS 25th Annual "New Ideas for the New Year" Virtual Investor Conference on January 14, 2025 at 10:15 a.m. ET.
A live audio webcast will be available via the Investors section of our website, www.westpharma.com.
About West
West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of life-saving and life-enhancing medicines for patients. With 10,000 team members across 50 sites worldwide, West helps support our customers by delivering approximately 43 billion components and devices each year.
Headquartered in Exton, Pennsylvania, West in its fiscal year 2023 generated $2.95 billion in net sales. West is traded on the New York Stock Exchange (NYSE: WST) and is included in the Standard & Poor's 500 index. For more information, visit www.westpharma.com.
All trademarks and registered trademarks used in this release are the property of West Pharmaceutical Services, Inc. or its subsidiaries, in the United States and other jurisdictions, unless otherwise noted.
View original content to download multimedia:https://www.prnewswire.com/news-releases/west-pharmaceutical-services-to-present-at-the-cjs-25th-annual-new-ideas-for-the-new-year-investor-conference-302343236.html
SOURCE West Pharmaceutical Services, Inc.
Ausgewählte Hebelprodukte auf West Pharmaceutical Services
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf West Pharmaceutical Services
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Nachrichten zu West Pharmaceutical Services Inc.
Analysen zu West Pharmaceutical Services Inc.
Datum | Rating | Analyst | |
---|---|---|---|
06.11.2012 | West Pharmaceutical Services hold | Jefferies & Company Inc. | |
14.05.2010 | West Pharmaceutical Services neutral | UBS AG | |
06.11.2007 | West Pharmaceutical Services buy | UBS AG | |
08.10.2007 | West Pharmaceutical Services neues Kursziel | UBS AG | |
20.08.2007 | West Pharmaceutical Services Ersteinschätzung | UBS AG |
Datum | Rating | Analyst | |
---|---|---|---|
06.11.2007 | West Pharmaceutical Services buy | UBS AG |
Datum | Rating | Analyst | |
---|---|---|---|
06.11.2012 | West Pharmaceutical Services hold | Jefferies & Company Inc. | |
14.05.2010 | West Pharmaceutical Services neutral | UBS AG | |
08.10.2007 | West Pharmaceutical Services neues Kursziel | UBS AG | |
20.08.2007 | West Pharmaceutical Services Ersteinschätzung | UBS AG |
Datum | Rating | Analyst | |
---|---|---|---|
Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar. Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für West Pharmaceutical Services Inc. nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen